Printer Friendly

Glenmark Pharmaceuticals granted final FDA approval to market generic version of Rythmol SR.

M2 PHARMA-September 11, 2017-Glenmark Pharmaceuticals granted final FDA approval to market generic version of Rythmol SR


India-based Glenmark Pharmaceuticals (NSE: GLENMARK) has been granted final approval by the US health regulator to market its generic version of Rythmol SR capsules, the company confirmed on Monday.

Rythmol SR capsules are indicated as an anti-arrhythmic medication, used in the treatment of illnesses whose symptoms include rapid heartbeats.

The US Food and Drug Administration (FDA) granted its approval for Propafenone Hydrochloride extended-release capsules USP, 225 mg, 325 mg and 425 mg.

Rythmol SR is a product of GlaxoSmithKline LLC.

The approval marks the company's 123rd product to gain approval for commercialisation in the US marketplace. It also has 63 Abbreviated New Drug Applications (ANDA) currently pending approval with the FDA.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 11, 2017
Previous Article:Innate Pharma presents new preclinical data for its first-in-class clinical stage antibodies IPH5401 and monalizumab.
Next Article:Miralles Named Chief Executive Officer at Vividion Therapeutics.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters